- Home
- MNRO vs NUVB Comparison
MNRO vs NUVB Comparison
Compare MNRO & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- NUVB
- Stock Information
- Founded
- MNRO 1957
- NUVB 2018
- Country
- MNRO United States
- NUVB United States
- Employees
- MNRO N/A
- NUVB N/A
- Industry
- MNRO Automotive Aftermarket
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- MNRO Consumer Discretionary
- NUVB Health Care
- Exchange
- MNRO Nasdaq
- NUVB Nasdaq
- Market Cap
- MNRO 658.9M
- NUVB 774.1M
- IPO Year
- MNRO 1991
- NUVB N/A
- Fundamental
- Price
- MNRO $18.71
- NUVB $2.21
- Analyst Decision
- MNRO Hold
- NUVB Strong Buy
- Analyst Count
- MNRO 2
- NUVB 6
- Target Price
- MNRO $25.50
- NUVB $7.67
- AVG Volume (30 Days)
- MNRO 956.1K
- NUVB 1.7M
- Earning Date
- MNRO 01-29-2025
- NUVB 03-03-2025
- Dividend Yield
- MNRO 5.99%
- NUVB N/A
- EPS Growth
- MNRO N/A
- NUVB N/A
- EPS
- MNRO 0.62
- NUVB N/A
- Revenue
- MNRO $1,210,419,000.00
- NUVB $2,162,000.00
- Revenue This Year
- MNRO N/A
- NUVB N/A
- Revenue Next Year
- MNRO $2.64
- NUVB $374.06
- P/E Ratio
- MNRO $30.34
- NUVB N/A
- Revenue Growth
- MNRO N/A
- NUVB N/A
- 52 Week Low
- MNRO $18.29
- NUVB $1.67
- 52 Week High
- MNRO $33.98
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- MNRO 33.04
- NUVB 37.58
- Support Level
- MNRO $18.74
- NUVB $2.16
- Resistance Level
- MNRO $19.92
- NUVB $2.38
- Average True Range (ATR)
- MNRO 0.70
- NUVB 0.12
- MACD
- MNRO 0.14
- NUVB 0.00
- Stochastic Oscillator
- MNRO 22.70
- NUVB 16.13
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).